Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15282103 | 0.82 | NFE2L2 (0.52) | KDM4EENPP2FDPSNFE2L2P4HB | |
| SCHEMBL10331382 | 0.82 | NFE2L2 (0.52) | KDM4EENPP2FDPSNFE2L2P4HB | |
| SCHEMBL27524881 | 0.79 | KDM4E (0.43) | KDM4EENPP2FDPSNFE2L2P4HB | |
| SCHEMBL6349916 | 0.78 | KDM4E (0.42) | KDM4EENPP2FDPSNFE2L2ESR1 | |
| SCHEMBL9105595 | 0.78 | VCP (0.51) | KDM4EENPP2FDPSNFE2L2P4HB | |
| SCHEMBL9105604 | 0.78 | VCP (0.51) | KDM4EENPP2FDPSNFE2L2P4HB | |
| SCHEMBL19595030 | 0.78 | KDM4E (0.46) | KDM4EENPP2FDPSESR1 | |
| SCHEMBL6349913 | 0.78 | KDM4E (0.42) | KDM4EENPP2FDPSNFE2L2ESR1 | |
| SCHEMBL4716233 | 0.75 | KDM4E (0.40) | KDM4EENPP2FDPSNFE2L2P4HB | |
| SCHEMBL4716231 | 0.75 | KDM4E (0.40) | KDM4EENPP2FDPSNFE2L2P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |